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Abstract
Infective endocarditis (IE) is a life-threatening disease, establishing a diagnosis is often challenging. The aim of this pro-
spective study was to evaluate and compare the diagnostic performance of the combined use of single photon emission 
tomography and computed tomography with technetium99m-hexamethylpropyleneamineoxime—labeled leukocytes (99mTc-
HMPAO-SPECT/CT) with transthoracic echocardiography (TTE) in patients with suspected IE. We enrolled 40 consecutive 
patients (12 females, 28 males, mean age: 58.6 ± 18) with suspected IE in the years 2015–2016. All patients underwent 
clinical evaluation, TTE and 99mTc-HMPAO-SPECT/CT for the assessment of lesions typical for IE. Scans were evaluated 
for the presence and location of increased radioactivity foci, corresponding to the accumulation of radiolabeled leukocytes 
in inflammatory lesions. After 6 months, the patients were re-evaluated clinically and with TTE. Final IE diagnosis was 
established in 14 (35%) patients. Lesions typical for IE were shown in 28 (70%) TTEs and 16 (40%) 99mTc-HMPAO-SPECT/
CTs. The latter tests were characterized by 90% accuracy, 93% sensitivity, 88% specificity, 96% negative predictive value 
(NPV), 81% positive predictive value (PPV). TTE demonstrated 60% accuracy, 93% sensitivity, 42% specificity, 92% NPV, 
and 46% PPV. 99mTc-HMPAO-SPECT/CT was characterized by a lower number of false-positive results compared to TTE 
(3 vs. 15). In patients with suspected IE, 99mTc-HMPAO-SPECT/CT yields a smaller number of false-positive results, 
significantly higher diagnostic accuracy, specificity and PPV than TTE. It helps to differentiate IE infectious and sterile 
echocardiographic lesions and reduces by 27% the number of misdiagnosed IE classified in the ‘possible IE’ category by 
modified Duke Criteria.
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Introduction
Infective endocarditis (IE) is a life-threatening disease with 
heterogeneous clinical manifestations. It has become one of 
the four most common life-threatening infection syndromes 
[1]. Despite introducing therapeutic advances in the last 20 
years, the mortality rates associated with IE have not decreased 
[2]. Its heterogeneous nature, stemming from the diverse num-
ber of causative pathogens involved, as well as underlying 
cardiac comorbidities, hamper any straightforward diagno-
sis. IE consists of a variety of different types depending on 
the presence of intra-cardiac foreign materials, such as native 
valve IE (NVE), prosthetic valve IE (PVE) and device-related 
IE (CDRIE) [2]. The probability of IE is assessed with the 
modified Duke Criteria. Microbiology and echocardiography 
(transthoracic-TTE, transoesophageal-TEE) play key roles in 
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the initial diagnosis and management. Currently, there are no 
reliable, distinct biomarkers of IE [3]. TTE has a sensitivity 
for NVE and PVE diagnosis of 70% and 50%, respectively 
[4, 5]. Even though specificity for the use of TTE has been 
reported to reach 90%, echocardiogram without abnormalities 
typical for IE does not exclude infections and there are many 
factors hindering its interpretation [6]. Echocardiographic 
evaluation is particularly difficult in the case of pre-existing 
valvular lesions, valvular prostheses or intracardiac devices. 
On the other hand, false-positive results are associated with 
thrombi, Lambl’s excrescences, cusp prolapse, chordal rupture, 
fibroelastoma, and Libman–Sacks lesions [6].
Single photon emission tomography with technetium99m 
hexamethylpropyleneamine oxime-labelled autologous leu-
kocytes (99mTc-HMPAO-SPECT/CT) is an emerging tech-
nique in IE diagnostics. The accumulation of time-dependent 
radiolabelled leucocytes (99mTc-HMPAO-WBC) is regis-
tered to evaluate in vivo inflammatory lesions [7]. Recent 
European Society of Cardiology (ESC) guidelines have 
introduced 99mTc-HMPAO-SPECT/CT to IE diagnostics 
in selected clinical situations [6]. The main added value of 
this technique is its high specificity and detection of periph-
eral embolic events. Given recent published data, nuclear 
imaging was introduced into the PVE diagnostic pathway. 
99mTc-HMPAO-SPECT/CT should be used when the diag-
nosis of PVE remains only ‘possible’ or even ‘rejected’ but 
with a persisting high level of clinical suspicion, either for 
the diagnosis of cardiac involvement or for imaging embolic 
events. In addition, 99mTc-HMPAO-SPECT/CT has been 
shown to have a potential role in CDRIE diagnostics; how-
ever, the data produced via this technique has not been suf-
ficient to warrant its inclusion in the diagnostic pathway. 
Currently, 99mTc-HMPAO-SPECT/CT may be considered 
an additive tool in patients with suspected CDRIE, positive 
blood cultures and non-diagnostic echocardiography. This 
technique was reported to be useful for detecting left-ven-
tricular-assist device and prosthetic vascular graft infections 
[8, 9]. Still, 99mTc-HMPAO-SPECT/CT has not yet found 
its place in American Heart Association and American Col-
lege of Cardiology guidelines [1, 10].
Insufficient data on the properties of 99mTc-HMPAO-
SPECT/CT compared to TTE has driven the need to address 
this issue. The aim of this prospective study was to evaluate 
and compare the results and diagnostic utility of 99mTc-
HMPAO-SPECT/CT and TTE in patients with suspected IE.
Materials and methods
Study population
Over the period 2015–2016, we enrolled 40 consecutive 
adults with suspected IE based on the standard medical 
diagnostic process. Exclusion criteria included: pregnancy, 
lactation, renal replacement therapy, neutropenia (below 
1500 cells per microliter), and diagnosed coexisting neo-
plastic disease. All patients underwent clinical evaluation 
with modified Duke Criteria assessment. Workup included 
white blood cell (WBC) count, C-reactive protein (CRP), 
procalcitonin (PCT) and three sets of peripheral venous 
blood samples for microbiological diagnostics. According 
to the 99mTc-HMPAO-SPECT/CT patients were stratified 
into those with the presence of intracardiac foci (group 1, 
n = 16) and those without (group 2, n = 24).
Echocardiography
Participants had TTE for the evaluation of lesions typi-
cal for IE, namely, vegetation, abscess, new dehiscence 
of a prosthetic valve, pseudoaneurysm, perforation, fis-
tula, valve aneurysm. Exams were performed with Philips 
EPIQ7 (the Netherlands) device according to ESC guide-
lines at the time of patient enrolment, and then after a 
6-month follow up period [4, 6].
Scintigraphy
Radiolabelling procedures were carried out in line with the 
European Society of Nuclear Medicine guidelines (dose: 
370–740 MBq) [7]. Scans were performed in supine posi-
tion after 4–6 h and 20–24 h following intravenous 99mTc-
HMPAO-WBC injection [11]. Images were acquired using 
a dual-head, variable-angle Siemens Symbia T16 SPECT/
CT gamma camera (Germany). Computed tomography 
(CT) attenuation-corrected and noncorrected SPECT 
images were assessed in the coronal, transaxial, and sag-
ittal planes, as well as in tridimensional maximal-intensity 
projection cine mode. Matching pairs of CT transmission 
and radionuclide emission images were fused for hybrid 
imaging (Fig. 1).
The images obtained were evaluated for the presence 
and location of foci of increased radioactivity, which cor-
respond to the accumulation of radiolabelled leukocytes 
in inflammatory lesions. Scans were classified as negative 
when no sites of pathological uptake were observed, or as 
positive in the cases where there was at least one intracar-
diac focus of abnormal uptake, characterized by typical 
time-dependent radioactivity pattern [12]. The extent of 
infection was assessed with regards to the involvement of 
the native valves, heart valve prostheses, endocardium, 
cardiac device lodge and electrodes [12–14]. The exam 
included extracardiac inflammatory foci evaluation. Exams 
were evaluated by two blinded, experienced nuclear medi-
cine specialists.
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Follow‑up
All patients were followed for 6 months. After that period 
an outpatient visit was scheduled for clinical re-evaluation 
and TTE.
Statistical analysis
The Shapiro–Wilk test was used to assess conformity with 
a normal distribution. The continuous variables were com-
pared between groups using Student’s t-test for mean values, 
Fig. 1  99mTc-HMPAO-SPECT/CT—study in three projections axial 
(left), sagittal (middle) and coronal (right). Bottom panel presents CT 
scans. Corresponding SPECT sections are presented in middle row 
and fusion images (99mTc-HMPAO-SPECT/CT) are placed in upper 
row. 99mTc-HMPAO-SPECT/CT shows an accumulation of radiola-
beled leucocytes in the vicinity of an implanted electrode (arrows). In 
this case tracer uptake is consistent with CDRIE
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and the Mann–Whitney U test for distribution. Categorical 
variables were analysed using the χ2 test or Fisher’s exact 
test as appropriate. The results of 99mTc-HMPAO-SPECT/
CT, TTE, modified Duke Criteria were compared with the 
final clinical IE diagnosis, taking into account microbiologi-
cal testing. In all cases, there was a follow-up after 6 months 
and subsequent outpatient visit, with clinical re-evaluation 
and TTE being performed for IE final diagnosis verifica-
tion. The sensitivity, specificity, accuracy, negative predic-
tive value (NPV), and positive predictive value (PPV) were 
calculated based on the final diagnosis and follow-up obser-
vation, with 95% confidence intervals (CIs), and compared 
using the kappa statistic for inter-rater reliability evaluation. 
Statistical analyses were performed using SPSS 23.0 (SPSS 
Inc., Chicago, IL, USA). p-values < 0.05 were accepted as 
statistically significant.
Results
Study population
The characteristics of patients (12 females, 28 males) are 
shown in Table 1. There were no differences between groups 
regarding the demographic and clinical profile, CRP and 
PCT values (p > 0.05). Most study participants (80%) had 
a cardiac implantable electronic device. Overall 15% of 
patients presented with a pocket site infection. Implanted 
prosthetic heart valves were present in 22.5% of the study 
population. According to the modified Duke Criteria, 7 
patients (17.5%) had definite IE, 26 (65%) had possible IE, 
and 7 (17.5%) did not have IE.
Overall, 60% of blood cultures were negative. In the 
remaining patients with positive blood cultures, Staphy-
lococci were the most common causative pathogens (10 
patients, 63%), including 25% Staphylococcus aureus infec-
tions. In other cases, infection was caused by: Enterococci 
(19%), Klebsiella (19%), Streptococci (6%), Escherichia 
(6%), Proteus (6%), and Candida (6%). Overall, 45% of 
patients developed systemic inflammatory response syn-
drome (SIRS), 15% developed sepsis and 6% developed 
septic shock requiring inotropic support.
Transthoracic echocardiography
Lesions typical for IE in TTE were present in 70% of 
patients. Most often there was vegetation (86%), new val-
vular regurgitation (14%), and annular abscess (4%). Any 
echocardiographic features diagnostic for IE associated with 
heart valves were observed in 35% of participants. Based on 
the TTE assessment, there was a suspicion of PVE in seven 
cases (18%). Vegetation within the intracardiac portion of 
electrodes was observed in 62.5% of patients with implant-
able cardiac devices.
Scintigraphy
40% of 99mTc-HMPAO-SPECT/CTs classified as positive 
for IE and 5% showed isolated local device infection (LDI). 
The most common type of radiolabelled leukocyte accumu-
lation consistent with IE was CDRIE, which accounted for 
68.8% of the positive scans. Scintigraphy exams showed 
increased tracer uptake within native valves in 3 (7.5%) 
patients and within prosthetic valves IE was detected in 2 
(5%) patients. Among the native valves and valve prostheses, 
aortic valve involvement was usually observed. Involvement 
of the tricuspid valve and pulmonic valve was less frequently 
encountered. Extracardiac foci of increased radioactivity 
were observed in 47.5% of patients. These were detected in 
the gastrointestinal tract (47.3%), bones (15.8%), the respira-
tory system (10.5%) and the urinary tract (5.3%).
Diagnostic value
Final IE diagnosis was established in 14 (35%) patients, 2 
patients had isolated LDI, and the remaining 24 patients 
were classified as IE-negative through the complete follow-
up observation period. The most common type of endocardi-
tis was CDRIE, which accounted for 64.3% cases, followed 
by 21.4% of PVE and 14.3% of NVE. Thirteen (32.5%) 
patients were operated on followed by antimicrobial therapy 
(12 procedures of complete implantable device removal, 3 
valve replacement surgeries, 1 valve repair procedure), 1 
patient was treated with antimicrobial therapy alone, and 2 
patients with other disease-specific surgical procedures; 24 
patients received no treatment.
The results of endocarditis assessment by TTE, 99mTc-
HMPAO-SPECT/CT and modified Duke Criteria are shown 
in Table 2 and Fig. 2. For IE diagnosis, 99mTc-HMPAO-
SPECT/CT was characterized by 90% accuracy, 0.79 
Cohen’s kappa coefficient, 93% sensitivity, 88% specificity, 
96% NPV and 81% PPV. In this group, TTE was 60% accu-
rate and the kappa value was 0.29. The diagnostic value of 
TTE in identifying IE was characterized by 93% sensitivity, 
42% specificity, 92% NPV and 46% PPV.
Overall for IE, modified Duke Criteria (when a positive 
result for the test was defined as a definite category) had 76% 
accuracy and 0.44 kappa. This method had 43% sensitivity, 
96% specificity, 76% NPV and 86% PPV. However, when 
positive results were defined as both definite and possible 
categories, there was 48% accuracy, 0.12 kappa, 93% sensi-
tivity, 23% specificity, 86% NPV and 39% PPV.
Out of all of the diagnostic methods, radiolabelled leuco-
cyte scintigraphy had the highest accuracy and NPV for IE 
diagnosis. 99mTc-HMPAO-SPECT/CT was characterized 
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Table 1  Characteristics of patients included in the study
Variable Valuea Group  1a (n = 16) Group  2a (n = 24) p value
Age (years) 58.6 ± 18 59 ± 18 58 ± 19 0.98
Gender
 Female 12 (30%) 4 (25%) 8 (33%) 0.57
 Male 28 (70%) 12 (75%) 16 (67%)
Body mass (kg) 76 ± 15.7 71.7 ± 15.9 80.2 ± 14.7 0.15
Body high (cm) 171 ± 8.2 170 ± 7.5 172 ± 9 0.71
Body mass index (kg/m2) 25.9 ± 4.3 24.5 ± 4.2 27.4 ± 4.1 0.08
Body surface area  (m2) 1.88 ± 0.22 1.82 ± 0.22 1.93 ± 0.21 0.20
Heart failure
(NYHA I/II/III/IV)
30 (75%)
(5/10/11/4)
14 (87%)
(2/5/6/1)
16 (67%)
(3/5/5/3)
0.46
Diabetes mellitus 9 (22.5%) 4 (25%) 5 (21%) 0.76
Arterial hypertension 20 (50%) 5 (31%) 15 (63%) 0.053
Atrial fibrillation 12 (30%) 6 (38%) 6 (25%) 0.40
Chronic liver disease 7 (17.5%) 3 (19%) 4 (17%) 0.79
Cardiovascular implantable electronic 
device present
32 (80%) 15 (94%) 17 (71%) 0.08
 Pacemaker 18 (45%) 7 (44%) 11 (46%)
 ICD 9 (22.5%) 6 (38%) 3 (12%)
 CRT 5 (12.5%) 2 (12%) 3 (12%)
Years since implantation of device 8 ± 6.9 7.6 ± 6.2 8.1 ± 7.4 0.93
Implanted prosthetic heart valve 9 (22.5%) 4 (25%) 5 (21%) 0.76
 Aortic mechanical valve 4 (10%) 1 (6%) 3 (12%)
 Biological aortic valve 3 (7.5%) 1 (6%) 2 (8%)
 Mitral mechanical valve 2 (5%) 2 (12%) 0
 Mitral biological valve 1 (2.5%) 1 (6%) 0
Years since implantation of valve 10 ± 7.4 10.8 ± 10.5 7.5 ± 6.2 0.58
Maximum body temperature (°C) 37.59 ± 1 37.5 ± 0.82 37.6 ± 1.2 0.87
Fever 17 (42.5%) 7 (44%) 10 (42%) 0.89
Number of leukocytes in peripheral 
blood  (109/l)
9.83 ± 4.31 10.51 ± 4.69 9.37 ± 4.08 0.22
Number of neutrophils in peripheral 
blood  (109/l)
7.14 ± 4.12 7.63 ± 4.9 6.81 ± 3.58 0.58
C-reactive protein (mg/l) [median, 
q1–q3]
52.76 ± 0.29 [15.5 (3.0–58.5)] 65.48 ± 95.7 [30 (2.5–67)] 44.28 ± 69.05 [13 (3–49)] 0.57
Procalcitonin (ng/ml) [median, q1–q3] 2.45 ± 7.93 [0.05 (0.05–0.17)] 2.89 ± 10.96 [0.05 (0.05–0.25)] 2.16 ± 5.3 [0.05 (0.05–0.21)] 0.24
Left ventricle ejection fraction (%) 44.6 ± 17.8 42 ± 18 47 ± 18 0.54
Left ventricle end-diastolic diameter 
(mm)
56.26 ± 11.9 57 ± 14 56 ± 11 0.98
Right ventricle proximal outflow tract 
diameter (mm)
33.2 ± 7 34 ± 7 32 ± 7 0.49
Tricuspid annular plane systolic excur-
sion (mm)
18.1 ± 5.6 17 ± 6 19 ± 5 0.71
Right atrium area  (cm2) 22.2 ± 9.4 25 ± 12 20 ± 6 0.36
Left atrium area  (cm2) 24.8 ± 7.7 25 ± 9 25 ± 6 0.82
Pericardial effusion 4 (10%) 2 (12%) 2 (8%) 1.00
Echocardiographic lesions typical for 
IE
28 (70%) 14 (87%) 14 (58%) 0.04
Echocardiography positive for IE—
mitral valve
3 (7.5%) 1 (6%) 2 (8%) 1.00
Echocardiography positive for IE—
aortic valve
6 (15%) 2 (12%) 4 (16%) 0.72
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by a statistically significantly higher Cohen’s kappa coef-
ficient, accuracy, specificity and PPV than TTE. The appli-
cation of scintigraphy in IE diagnostic workup reduces the 
false-positive results rate in comparison to TTE (3 patients 
vs. 15 patients).
Compared to modified Duke Criteria, when a positive 
result for the test was defined as including both definite 
and possible categories, 99mTc-HMPAO-SPECT/CT had 
statistically significantly higher Cohen’s kappa coefficient, 
accuracy, specificity and PPV. When a positive result was 
defined solely as a definite category, then scintigraphy and 
modified Duke Criteria diagnostic parameters did not dif-
fer significantly; however, 99mTc-HMPAO-SPECT/CT 
was characterized by a lower rate of false-negative results 
(1 patient vs. 8 patients).
Discussion
Due to the on-going change in IE epidemiology, the 
affected patients are older, have more comorbidities and 
intracardiac devices [15–17]. Establishing an IE diagnosis 
According to the 99mTc-HMPAO-SPECT/CT patients were stratified into those with the presence of intracardiac foci (group 1) and those with-
out (group 2)
a Data are given as a number (percentage) for categorical data and as mean value ± one standard deviation or median (IQR) for continuous vari-
able
Table 1  (continued)
Variable Valuea Group  1a (n = 16) Group  2a (n = 24) p value
Echocardiography positive for IE—
tricuspid valve
3 (7.5%) 1 (6%) 2 (8%) 1.00
Echocardiography positive for IE—
pulmonic valve
1 (2.5%) 1 (6%) 0 (0%) 1.00
Vegetations 24 (60%) 12 (75%) 12 (50%) 0.12
Vegetations within an electrode 20 (50%) 12 (75%) 8 (30%) 0.01
Valvular vegetations 10 (24%) 4 (25%) 6 (25%) 1.00
New severe valve regurgitation (valve 
perforation or prosthetic valve 
dehiscence)
3 (7.5%) 1 (6%) 2 (8%) 1.00
Perivalvular abscess 1 (2.5%) 0 (0%) 1 (4%) 1.00
Valve aneurysm 1 (2.5%) 1 (6%) 0 (0%) 1.00
Extracardiac infectious foci in 99mTc-
HMPAO-SPECT/CT
19 (47.5%) 7 (44%) 12 (50%) 0.69
Table 2  Comparison of TTE, 99mTc-HMPAO-SPECT/CT, and modified Duke Criteria results in IE suspicion evaluation
Type of test Result for IE Patients 
with IE 
(n = 14)
Patients 
without IE 
(n = 26)
Kappa (95% 
CI)
Accuracy 
(95% CI)
Sensitivity 
(95% CI)
Specificity 
(95% CI)
NPV (95% 
CI)
PPV (95% 
CI)
99mTc-
HMPAO-
SPECT/CT
Positive 13 (93%) 3 (12%) 0.79 (0.59–
0.98)
0.90 (0.76–
0.97)
0.93 (0.66–
0.99)
0.88 
(0.7–0.98)
0.96 (0.78–
0.99)
0.81 
(0.6–0.93)Negative 1 (7%) 23 (88%)
TTE Positive 13 (93%) 15 (58%) 0.29 (0.07–
0.50)
0.60 (0.43–
0.75)
0.93 (0.66–
0.99)
0.42 (0.23–
0.63)
0.92 (0.61–
0.99)
0.46 (0.38–
0.55)Negative 1 (7%) 11 (42%)
Modified 
Duke 
Criteria 
(definite 
category)
Positive 6 (43%) 1 (4%) 0.44 (0.16–
0.72)
0.76 (0.66–
0.82)
0.43 (0.18–
0.71)
0.96 
(0.8–0.99)
0.76 (0.66–
0.83)
0.86 (0.44–
0.98)Negative 8 (57%) 25 (96%)
Modified 
Duke Cri-
teria (defi-
nite and 
possible 
categories)
Positive 13 (93%) 20 (77%) 0.12 (0–0.29) 0.48 (0.32–
0.64)
0.93 (0.66–
0.99)
0.23 (0.09–
0.44)
0.86 (0.44–
0.98)
0.39 (0.34–
0.46)Negative 1 (7%) 6 (23%)
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is a complex, multi-disciplinary process. Delayed diag-
nosis and treatment can lead to complications and worse 
clinical outcomes [18–22]. Due to the fact that 1-year mor-
tality from IE has not improved in over two decades, it is 
crucial to develop more accurate diagnostic tools [23, 24]. 
As previously shown, 60% of blood cultures were negative 
[25, 26]. Nuclear medicine may provide opportunities for 
personalized evaluation in order to choose the best thera-
peutic strategy [27, 28]. Nonetheless, data on the diag-
nostic performance of 99mTc-HMPAO-SPECT/CT is very 
limited [8, 11–14]. Systematic reviews have shown that 
it has 64–90% sensitivity, 36–100% specificity, 85–100% 
PPV and 47–81% NPV [29]. However, the most recent 
state of art meta-analysis on the role of nuclear imaging 
in IE identified three studies with a total of 207 patients 
who had radiolabelled leucocytes scintigraphy. The pooled 
sensitivity and specificity of 99mTc-HMPAO-SPECT/CT 
was 86% and 97%, respectively [30]. These findings are 
consistent with our results, which showed 93% sensitivity 
and 88% specificity.
Landmark IE studies investigating the diagnostic value 
of either 99mTc-HMPAO-SPECT/CT or positron emission 
tomography with fluorodeoxyglucose (18F-FDG PET) used 
clinical follow-ups as their reference standard [30]. Although 
this methodology has some inherent flaws, it is believed to 
be accurate by leading specialists in this field in the con-
text of IE characterization. Histopathological examination 
is considered to be the ‘gold standard’ for IE diagnosis [6]. 
Still, including histopathology in a study protocol also has 
its potential pitfalls and difficulties. Therefore, so far, no 
validation of nuclear imaging has been performed using his-
topathological examination.
99mTc-HMPAO-SPECT/CT is reported to be particu-
larly helpful in patients with a high clinical suspicion but 
previously inconclusive echocardiographic findings, and 
for differential diagnoses between septic and sterile veg-
etation, when echocardiographic, laboratory, and clinical 
tests provide contradictory results [12]. Similarly, in this 
study 99mTc-HMPAO-SPECT/CT was characterized by 
significantly higher specificity as well as a lower number of 
Fig. 2  Comparison of TTE, 
99mTc-HMPAO-SPECT/CT 
and modified Duke Criteria 
diagnostic value in IE suspicion 
evaluation. Accuracy, sensitiv-
ity, specificity, PPV, NPV are 
shown as values (%) with 95% 
confidence intervals
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false-positives compared to TTE (3 vs. 15). Since 99mTc-
HMPAO-SPECT/CT provides data on current radiolabelled 
leucocyte accumulation in inflammatory lesions, it was espe-
cially useful in echocardiographic lesion differentiation for 
those with on-going infections and inactive ones.
Transthoracic echocardiography has several advantages, 
such as wide-spread accessibility, low cost, high safety pro-
file, possibility of both anatomical and functional assess-
ment, which makes it the imaging modality of choice in 
majority of cardiac conditions, including IE. Even tough 
TEE is recommended (class I B) in selected groups of 
patients (with negative/non-diagnostic TTE, prosthetic 
heart valve or an intra-cardiac device) and is characterized 
with better diagnostic accuracy than TTE (sensitivity for 
the diagnosis of vegetation in NVE and PVE is for TEE 
respectively 96% and 92%), it has also several following 
limitations: semi-invasive character, requirement of patient’s 
cooperation or even sedation in selected patients or instable 
patients [6]. Moreover, both normal TTE and TEE do not 
completely exclude early stages of infection. In contrary, 
99mTc-HMPAO-SPECT/CT is available in highly special-
ized centers, is far more expensive and study protocol is 
24-h-long. Another drawback is radiation as a result of both 
CT and radioisotope administration.
Modified Duke Criteria, although of paramount impor-
tance, have significant limitations, such as low sensitivity for 
PVE diagnosis [31]. Moreover, 30% of patients with subse-
quently proven IE are labelled as merely ‘possible IE’ [32, 
33]. A reduction in the rate of misdiagnosed IE, previously 
classified as ‘possible IE’, contributes to the added value 
of 99mTc-HMPAO-SPECT/CT to the IE diagnostic process 
[6]. In this study, 26 (65%) patients were classified as ‘pos-
sible IE’. In this subgroup, 7 patients (27%) were diagnosed 
with IE, and, in all those cases, 99mTc-HMPAO-SPECT/CT 
results were true positives.
99mTc-HMPAO-SPECT/CT is characterized by high 
specificity in perivalvular regions for active infective pro-
cesses [34]. It has higher specificity for the diagnosis of 
PVE than 18F-FDG PET, a modality especially useful in 
IE diagnostic workup [35–40]. However, 99mTc-HMPAO-
WBC accumulation may be low in drained or encapsulated 
abscesses, or in the case of infection with non-pyogenic bac-
teria [27]. We observed one case of a false negative 99mTc-
HMPAO-SPECT/CT result in a perivalvular abscess in the 
course of PVE. On the other hand, there were three false-
positive scintigraphy results; in one patient, this was most 
probably related to an autoimmune disorder.
The diagnosis of IE based on standard medical tools with-
out nuclear imaging can be accurate, yet it is very difficult to 
assess the precise localization and range of the infection. It 
is especially difficult given the fact that most patients with 
suspected IE in clinical practice have multiple comorbidities, 
have undergone multiple cardiac invasive procedures, and 
often have either a prosthetic valve or an implantable device. 
In this study, 99mTc-HMPAO-SPECT/CT was useful not 
only in identifying IE, but also in delimiting the scope of 
the infection, which is crucial for choosing the appropriate 
therapy for patients. In this group, none of patients who had 
99mTc-HMPAO-SPECT/CT results consistent with LDI 
developed CDRIE.
99mTc-HMPAO-SPECT/CT also allows for the detec-
tion of IE complications such as septic embolic events [6, 
41]. 30% of patients with IE have clinical signs of embo-
lization [42]. We detected extracardiac inflammatory foci 
in 47.5% of scans. This rate is consistent with results from 
the largest study evaluating the diagnostic value of 99mTc-
HMPAO-SPECT/CT (131 patients), where septic emboli 
were detected in 41% of patients [12].
Limitations
All patients enrolled to the study were Caucasian. This pro-
ject was performed in a single department of nuclear medi-
cine. Study results need to be validated in a larger, multi-
centre study.
Conclusions
In patients with suspected IE, 99mTc-HMPAO-SPECT/CT 
provides a lower number of false-positive results, and sig-
nificantly higher accuracy, specificity and PPV than TTE. 
Furthermore, this technique helps to differentiate IE echo-
cardiographic morphologic lesions—those with on-going 
infections and inactive ones. In addition, the use of 99mTc-
HMPAO-SPECT/CT leads to a reduction by 27% of the rate 
of misdiagnosed IE classified in the ‘possible IE’ category 
by modified Duke Criteria. 99mTc-HMPAO-SPECT/CT 
may be an invaluable tool not only in diagnosing IE, but 
also in defining its localization and range, which is particu-
larly important in differentiating between CDRIE and LDI. 
Overall, 99mTc-HMPAO-SPECT/CT seems to be a useful 
technique within the IE diagnostic pathway; nevertheless, in 
future, multicentre studies will be needed for further evalu-
ation of this method.
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